Contrasting Profusa (PFSA) and Its Peers

Profusa (NASDAQ:PFSA) is one of 27 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its peers? We will compare Profusa to related companies based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Risk & Volatility

Profusa has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Profusa’s peers have a beta of 1.80, indicating that their average stock price is 80% more volatile than the S&P 500.

Profitability

This table compares Profusa and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Profusa Competitors	-569.68%	-122.96%	-53.63%

Institutional & Insider Ownership

9.8% of Profusa shares are held by institutional investors. Comparatively, 19.3% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 11.4% of Profusa shares are held by company insiders. Comparatively, 19.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Profusa and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Profusa Competitors	80	82	161	7	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 55.05%. Given Profusa’s peers stronger consensus rating and higher possible upside, analysts plainly believe Profusa has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares Profusa and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profusa	N/A	-$8.71 million	-0.01
Profusa Competitors	$61.19 million	-$32.64 million	5.16

Profusa’s peers have higher revenue, but lower earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Profusa peers beat Profusa on 10 of the 13 factors compared.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.